We have already tested the in vitro activity of the major product of this pathway, 20(OH)D3, and its metabolites, finding that they show antiproliferative activity against cultured melanoma cells, acting as biased agonists on the VDR [43,45,46]. The gene discussed is VDR; the disease is melanoma.